but Stamp argued that the allopurinol dose used in the study — 300 mg/d — “may not be enough for many patients who have gout. Dose-restricting allopurinol is one way to demonstrate that an ...

Diagnosis Tophaceous gout associated with urate nephropathy in a patient intolerant to allopurinol ... was reduced to 1 mg daily, as was given previously. Despite concurrent treatment with ...

Subjects received 100–300 mg/day of allopurinol plus standard therapy (n = 26), or standard therapy alone (n = 26). Standard therapy included antihypertensives and lipid-lowering drugs.

XORTX Therapeutics (XRTX) announces the launch of a new late stage program to treat gout. The new drug development program – XRx-026 – will ...

With the clinical development of XORLO TM1 having advanced sufficiently, including completion of a pivotal program, XORTX is initiating discussions for the XRx-026 program with the US Food and Drug ...

Previously, oxypurinol was granted ODD for allopurinol intolerant gout. Dr. Allen Davidoff commented, “Oxypurinol has been demonstrated to be safe and effective in clinical studies focused on the ...